ThomasEWitzigMD

Professor of Medicine, Mayo Alix School of Medicine Consultant, Division of Hematology Distinguished Senior Leader in Translational Research, Mayo Clinic Comprehensive Cancer Center

Join to view full profile

Dr. Witzig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Witzig's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Summary

Dr. Thomas Witzig is a hematologist in Rochester, MN, affiliated with Mayo Clinic Hospital - Rochester. He received his medical degree from the University of Illinois College of Medicine and has practiced for 38 years at the Mayo Clinic in Rochester, MN. He is experienced in hematologic oncology (focus lymphoma) and IgG4-related diseases. His lab research is focused on developing new treatments around impairing the DNA damage response in blood cancer cells. He also focuses on nutritional oncology (Vitamins D, C, and Magnesium). He has more than 400 publications.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1982 - 1986
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1979 - 1982
University of Illinois College of MedicineClass of 1979

Certifications & Licensure

MN State Medical License 1982 - 2025
IA State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Barbara Woodward Lips Professor 1 2023-2024

Clinical Trials

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Start of enrollment: 1998 Feb 01
Completed
Phase 2
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy Start of enrollment: 1998 Dec 01
Completed
Phase 3
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 1999 Aug 01
Completed
Phase 2
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease Start of enrollment: 1999 Jul 01
Completed
Phase 2
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Start of enrollment: 2000 Oct 01
Completed
Phase 2
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2001 Apr 01
Terminated
Phase 1, Phase 2
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma Start of enrollment: 2004 Dec 01
Terminated
Phase 2
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma Start of enrollment: 2006 Jan 01
Completed
Phase 2
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Start of enrollment: 2003 Jul 01
Completed
Phase 3
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Start of enrollment: 2005 Aug 01
Completed
Phase 2
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2006 Mar 01
Completed
Phase 1
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2004 Oct 01
Completed
Phase 1, Phase 2
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2008 Apr 01
Completed
Phase 2
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Start of enrollment: 2007 Aug 29
Completed
Phase 1, Phase 2
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Mar 01
Completed
Phase 2
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2008 Jul 01
Completed
Phase 2
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Start of enrollment: 2008 Aug 01
Completed
Phase 2
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 2
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Start of enrollment: 2011 Jan 10
Completed
Phase 1, Phase 2
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant Start of enrollment: 2011 Aug 12
Completed
Phase 2
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2012 Dec 01
Completed
Early Phase 1
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Start of enrollment: 2013 Mar 06
Recruiting
Not Applicable
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Start of enrollment: 2016 Jan 19
Completed
Not Applicable
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia Start of enrollment: 2018 Mar 23
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screening.
Suheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, Robyn L Kuchler, Grzegorz S Nowakowski
American Journal of Hematology. 2025-01-01
Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.
Allison M Bock, Kerstin Wenzl, Joseph P Novak, Matthew E Stokes, Melissa A Hopper
Hematological Oncology. 2025-01-01
Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome.
Adi Zoref-Lorenz, Thomas E Witzig, James R Cerhan, Michael B Jordan
Leukemia & Lymphoma. 2024-12-10

Journal Articles

Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia Cells
Richard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal Lymphoma
Lisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood

Abstracts/Posters

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients...
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic S...
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Tria...
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience
Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
2019 ASCO Annual Meeting - 6/1/2019
Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-cell LymphomaDecember 13th, 2021
NCI Awards $12.4 Million Lymphoma Research Grant to University of Iowa and Mayo ClinicSeptember 18th, 2017
Diagnosis of Autoimmune Pancreatitis: The Evolution of Diagnostic Criteria for a Rare DiseaseJune 17th, 2017
Join now to see all

Grant Support

P2 - Signal Transduction Inhibitor Therapy For LymphomaNational Cancer Institute2010–2011
Signal Transduction Inhibitor Therapy For LymphomaNational Cancer Institute2007–2011
Signal Transduction Inhibitor Therapy For LymphomaNational Cancer Institute2007–2009
PI3K Pathway Inhibitors For Mantle Cell LymphomaNational Cancer Institute2005–2006
Enhancement Of Lymphoma Radioimmunotherapy By CPG ODNNational Cancer Institute2002
Radioimmunotherapy For LymphomaNational Cancer Institute2001–2002
HematologyNational Cancer Institute2001–2002
Characterization And Growth Of Clonally Related Myeloma CellNational Cancer Institute2000–2002
Apoptosis And %S As Prognostic Factors For Colon CancerNational Cancer Institute1998–1999